INVESTMENTS

ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer. Our target technologies are breakthroughs with unmet clinical need, strong IP protection, and the appeal to become a must-have for strategic players. We completed many successful transactions with a superior return on invested capital in partnerships with the leading US and EU venture groups.

LIFE CHANGING

INVESTMENTS

OUR TEAM'S

ATEA Pharmaceuticals - biopharmaceutical company Logo
ATEA Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Atea went public at a valuation of $1.9 billion which makes over 30x of our Series A investment back in 2014 at pre-money $10 million. The company made an exclusive partnership with Roche for the ex-US rights ahead of the IPO.
NEXT: Iridia
NASDAQ: AVIR, IPO in Oct 2020
Iridia
Iridia, a synthetic biology company backed by Western Digital and LifeSci Venture Partners, is developing the world's first commercially attractive, DNA-based data storage solution with a highly parallel format.

The company's technology enables an array of nanomodules with the potential to store data at exceptionally high density.
NEXT: Syndax Pharmaceuticals
Iridia - synthetic biology company Logo
Syndax Pharmaceuticals
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. The company’s CEO is Briggs W. Morrison, a managing director of MPM Capital and a former head of R&D at AstraZeneca. Syndax pipeline includes a highly selective inhibitor of the Menin–MLL binding interaction to treat acute leukemias, axatilimab, a monoclonal antibody that blocks the colony-stimulating factor 1 (CSF-1) receptor against chronic Graft versus Host Disease, and entinostat, a class I HDAC inhibitor.
NEXT: Epic Sciences
NASDAQ: SNDX, IPO in Feb 2016
Syndax is a clinical-stage biotech company developing an innovative pipeline of cancer therapies. Logo
Epic Sciences
Epic Sciences developed susceptible tests that molecularly characterize circulating tumor cells in the blood to open up a new way to detect cancer and personalize/monitor treatments. Epic Sciences' an unbiased approach using the Comprehensive Cancer Profiling liquid biopsy platform sees those rare cells that others miss. Epic gives cancer patients and their physicians the clear, accurate insights they need to choose the best course of therapy.
NEXT: Amolyt Pharma
Epic Sciences the power of clarity Logo
Amolyt Pharma
Amolyt Pharma is a clinical-stage biotechnology company developing life-changing treatments for patients suffering from rare endocrine and metabolic diseases with a best-in-class safety profile and efficiency. Amolyt's next-gen therapeutic peptides imitate the behaviour of hormones with long-term receptor activation and possess a better physiological effect than therapies based on recombinant proteins. AZP-3601, Amolyt's lead clinical candidate, is a therapeutic peptide in development as a potential treatment for hypoparathyroidism, a rare endocrine disorder.
NEXT: Tobira Therapeutics
Epic Sciences the power of clarity Logo
Tobira Therapeutics
Tobira developed cenicriviroc (CVC), a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a liver scarring disease that affects millions of people and is growing alongside the high rates of obesity and diabetes, but has no approved therapies.

In September 2016, Allergan acquired Tobira Therapeutics in a US$1.7 billion deal, or 19 times its previous market value.
NEXT: Triumvira Immunologics
Tobira Therapeutics logo
Triumvira Immunologics
Triumvira Immunologics is developing a differentiated technology platform to produce autologous and allogenic T-Сell Antigen Coupler (TAC) therapeutics addressing solid tumors and blood cancer with better safety profile and efficiency in comparison with conventional CAR-T approach.

In March 2021, Triumvira submitted an IND application to FDA, then started the enrollment of the referred patients into Phase I trials in collaboration with MD Anderson Cancer Center, the leading clinical trials research center in the US.
NEXT: Arpeggio Biosciences
Tobira Therapeutics logo
Arpeggio Biosciences
Arpeggio is developing the drug discover technology that enables direct reading of cell transcription changes and screening the activity of tens of thousands compounds in both malfunctioning and healthy cells when they are exposed to various drugs.

The company has signed more than 40 strategic partnership agreements with major pharmaceutical companies, which confirms the considerable interest in the platform from the industry. Arpeggio's partners include such established global players as Pfizer, Janssen, Genentech, Novartis, etc.
NEXT: ATEA Pharmaceuticals
Tobira Therapeutics logo

LIFE SCIENCES

Fundamental factors fuel the steady growth of the healthcare markets worldwide despite any financial vulnerabilities, with the latest years setting a new sustainable record. Both public and private healthcare costs are constantly increasing in absolute and relative terms, notwithstanding financial vulnerabilities, thus creating stable multi-billion markets and second to none investment opportunities.

WHY

POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
diagram, POPULATION RISE AND AGING ARE DRIVING INCREASED GOVERNMENT AND PRIVATE SPENDING
THAT FUELS UNPRECEDENTED GROWTH
diagram, THAT FUELS UNPRECEDENTED GROWTH
CONSISTENT INVESTMENTS BY VENTURE CAPITAL FIRMS IN LIFE SCIENCES* PROJECTS
* Life Sciences (LS) is composed of Pharma & Biotech and Healthcare
diagram, CONSISTENT INVESTMENTS BY VENTURE CAPITAL FIRMS IN LIFE SCIENCES* PROJECTS
ARE REWARDED IN THE NUMEROUS IPO’s
Source: PwC/NVCA Moneytree report, HBM Pharma, PitchBook
diagram, ARE REWARDED IN THE NUMEROUS IPO’s
AND EXPANDING M&A ACTIVITY BY BIG PHARMA
diagram, AND EXPANDING M&A ACTIVITY BY BIG PHARMA
Download ATEM's Life Sciences industry report to learn more about healthcare's accommodative liquidity and bulletproof fundamentals.

OUR GAME-CHANGING

STRATEGY

Get efficient access to one of the most exciting and private asset classes of Life Sciences innovations

Landmark deal flow

of major like-minded US and Western Europe VC firms and selected private projects of successful serial entrepreneurs

Real-time insights

from the most connected Advisory Board into investment opportunities and emerging Big Pharma needs

Industrial-quality diligence

to optimize decision-making process and risk management

INVEST IN

CURES

ATEM acts in strategic partnerships with the world’s leading venture firms and possesses critical mass, topnotch expertise, industrial quality diligence, and professional board-level control to identify superior technologies with healthy returns to investors

INVESTNENT

THEMES

30% — Scientific Home-Runs

Early-stage breakthrough science managed by high-caliber serial entrepreneurs with unmatched track-record of success

40% — Next Gen Bioplatforms

Fast-growing biopharma companies with a diversified and robust pipeline and sound promise to go public or ready for M&A within one to three years

30% — Medicine Automation

Post-revenue companies in AI drug discovery, alternative care, digital therapeutics, and robotics with potential for multi-billion growth

BECOME A PART OF THE NEXT

SCIENTIFIC BREAKTHROUGH

IMMUNO-ONCOLOGY

Projects with cure ambition,
novel MoA, use of innovative
delivery platforms, and signs of efficacy

AUTOIMMUNE DISEASES

Technologies saving lives with robust preclinical and clinical data and manageable regulatory path

RARE DISEASES

Customizable therapeutics for people with genetic diseases that have no treatment or cure

NEUROLOGY

Projects that let people enjoy their life experiences, with human proof-of and a well-understood mechanism of action

OUR

LEADERSHIP

Our international team combines big picture perspective and long-term technology view with decades of diverse experience in investments, scientific research, clinical development, intellectual property, and operations.

Team
Advisory Board
Anton GOPKA
Managing Partner
Elena MALEY
Managing Partner
Zachar LEIKIN, M.D.
Medical Advisor
Peter STAROKADOMSKY, Ph.D.
Scientific Partner
Yulii BOGATYRENKO
Venture Partner
Ilia ARDABEVSKII
Analyst
Joseph CAMARDO, M.D.
Bruce BURLINGTON, M.D.
Ed GODBER, MBA
Rivka KREITMAN, Ph.D.
Prof. Roberto PELLICCIARI
Viktor KOTELIANSKY, M.D.

KNOWLEDGE

CENTER

See more in ATEM Telegram channel
go to channel
go to channel

GET IN TOUCH

Subscribe to our newsletters